We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 07, 2021

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor

JAMA Oncology


Additional Info

JAMA Oncology
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
JAMA Oncol 2020 Dec 30;[EPub Ahead of Print], K Kalinsky, F Hong, CK McCourt, JC Sachdev, EP Mitchell, JA Zwiebel, LA Doyle, LM McShane, S Li, RJ Gray, LV Rubinstein, D Patton, PM Williams, SR Hamilton, BA Conley, PJ O'Dwyer, LN Harris, CL Arteaga, AP Chen, KT Flaherty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading